Professur für Innere Medizin (Nephrologie und Hypertensiologie)

EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES - A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Idorn T, Mahaffey K, Marso S, et al. Conference contribution EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) Perkovic V, Bain S, Bakris G, Buse J, Gondolf T, Idorn T, Lausvig N, et al. Conference contribution Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial" (2019) Mann J, Fonseca V, Mosenzon O, Raz I, Goldman B, Idorn T, von Scholten BJ, Poulter NR Journal article, Note Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference (2019) Cheung AK, Chang TI, Cushman WC, Furth SL, Ix JH, Pecoits-Filho R, Perkovic V, et al. Journal article Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study (2019) Combe C, Mann J, Goldsmith D, Dellanna F, Zaoui P, London G, Denhaerynck K, et al. Journal article Health-related quality of life in people with type 2 diabetes participating in the LEADER trial (2019) Nauck MA, Buse JB, Mann J, Pocock S, Bosch-Traberg H, Frimer-Larsen H, Ye Q, Gray A Journal article Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk (2019) Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann J, Mancia G, et al. Journal article Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events (2018) Husain M, Bain SC, Mann J, Nauck M, Poulter N, Baeres FMM, Goldman B, et al. Conference contribution Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes (2017) Clase CM, Barzilay J, Gao P, Smyth A, Schmieder R, Tobe S, Teo KK, et al. Journal article